2025
Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion
Belinsky G, Ruan J, Fattahi N, Mehta S, Boddupalli C, Mistry P, Nair S. Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion. Human Molecular Genetics 2025, 34: 952-966. PMID: 40197748, PMCID: PMC12085781, DOI: 10.1093/hmg/ddaf045.Peer-Reviewed Original ResearchGD miceImmune dysregulationGaucher diseaseExpansion of monocytesImmune cell deconvolutionKnockout modelsBone marrow microenvironmentGlucocerebrosidase activityC57BL/6 J backgroundDeficient glucocerebrosidase activityGaucher cell infiltrationInfluence disease severityGD biomarkersGD pathologyGD pathophysiologyLysosomal storage disorderImmune landscapeDendritic cellsHematopoietic stemMarrow microenvironmentAccumulation of glucosylceramideVav-CreBone marrowCell infiltrationHematopoietic cells
2024
P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment
Matulis S, Barwick B, Bombin S, Ackley J, Gupta V, Hill G, Green D, Riddell S, Lonial S, Dhodapkar M, Boise L. P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)02137-2.Peer-Reviewed Original Research
2023
Secretory MPP3 reinforce myeloid differentiation trajectory and amplify myeloid cell production
Kang Y, Paik H, Zhang S, Chen J, Olson O, Mitchell C, Collins A, Swann J, Warr M, Fan R, Passegué E. Secretory MPP3 reinforce myeloid differentiation trajectory and amplify myeloid cell production. Journal Of Experimental Medicine 2023, 220: e20230088. PMID: 37115584, PMCID: PMC10140385, DOI: 10.1084/jem.20230088.Peer-Reviewed Original ResearchConceptsGranulocyte/macrophage progenitorsHematopoietic stem cellsMyeloid differentiationMajor functional contributorsNovel regulatory functionLocal bone marrow (BM) microenvironmentSteady-state hematopoiesisDifferentiation trajectoriesRecent lineagesMyeloid cell productionCellular heterogeneityBone marrow microenvironmentRegulatory functionsFunctional contributorsMacrophage progenitorsSecretory cellsStem cellsMPP3Blood productionMarrow microenvironmentCell productionDifferentiationRapid productionDistinct subsetsMyelopoiesisCell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling
Feng X, Sun R, Lee M, Chen X, Guo S, Geng H, Müschen M, Choi J, Pereira J. Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling. ELife 2023, 12: e83533. PMID: 36912771, PMCID: PMC10042536, DOI: 10.7554/elife.83533.Peer-Reviewed Original ResearchConceptsMesenchymal stem cellsLymphotoxin beta receptorLeukemic cellsBeta receptorsLeukemic cell growthBone marrow microenvironmentStem cellsTransplant recipientsAML cellsMyeloblastic leukemiaMouse modelBone marrowLeukemia growthLymphotoxin α1β2Marrow microenvironmentPharmacological disruptionLymphopoiesisReceptorsHematopoietic outputMolecular mechanismsErythropoiesisDNA damage response pathwayCell growthCellsPhysiological mechanisms
2021
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2
Nobre A, Risson E, Singh D, Di Martino J, Cheung J, Wang J, Johnson J, Russnes H, Bravo-Cordero J, Birbrair A, Naume B, Azhar M, Frenette P, Aguirre-Ghiso J. Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2. Nature Cancer 2021, 2: 327-339. PMID: 34993493, PMCID: PMC8730384, DOI: 10.1038/s43018-021-00179-8.Peer-Reviewed Original ResearchConceptsMesenchymal stem cellsDTC dormancyHematopoietic stem cell quiescenceStem cellsStem cell quiescenceBone morphogenetic proteinTGF-β2Niche homeostasisMorphogenetic proteinsCell quiescenceBone marrow microenvironmentGenetic depletionP27 inductionDormancyConditional knockoutMarrow microenvironmentMetastatic outgrowthEstrogen receptor-positive BCExtrinsic factorsGrowth factorCellsTumor cellsBone relapseSystemic recurrenceBreast cancer
2020
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era
Bewersdorf JP, Zeidan AM. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. Expert Review Of Hematology 2020, 13: 1189-1199. PMID: 33076714, PMCID: PMC7722191, DOI: 10.1080/17474086.2020.1839887.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBone MarrowClinical Trials as TopicCombined Modality TherapyDNA MethylationDrugs, InvestigationalForecastingHistone CodeHumansHydroxyureaInflammationInterferon-alphaJanus Kinase 2Molecular Diagnostic TechniquesMolecular Targeted TherapyMutation, MissenseNitrilesPolycythemia VeraPyrazolesPyrimidinesSignal TransductionTherapies, InvestigationalThrombocythemia, EssentialThrombophiliaThrombosisTumor MicroenvironmentConceptsEssential thrombocythemiaPolycythemia veraNovel agentsPV patientsTreatment selectionHigh-risk essential thrombocythemiaAberrant immune regulationFirst-line treatmentDisease-modifying potentialRecent clinical trialsNegative myeloproliferative neoplasmsBone marrow microenvironmentImmune pathobiologyCombination therapyClinical trialsClinical studiesImmune regulationPV pathogenesisConference abstractsBCR-ABL1Individualized approachMolecular testingClonal proliferationMyeloproliferative neoplasmsPatientsHyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells 2020, 9: 2310. PMID: 33080779, PMCID: PMC7603052, DOI: 10.3390/cells9102310.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTumor lysis syndromeAcute myeloid leukemiaLeukemic blastsMyeloid leukemiaCell adhesion moleculeAggressive intravenous fluid hydrationWhite blood cell countEndothelial cellsAdhesion moleculesDevelopment of leukostasisIntravenous fluid hydrationManagement of DICMainstay of therapyLife-threatening complicationsBlood cell countLeukemic stem cell survivalBone marrow microenvironmentIntensive chemotherapyIntravascular coagulationLysis syndromeFluid hydrationSupportive treatmentAdverse prognosisAML patientsInflammatory cytokines
2018
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal Of Haematology 2018, 101: 260-271. PMID: 29742289, DOI: 10.1111/ejh.13092.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMolecular pathogenesisGene expression profilingSignal transduction elementsDevelopment of MDSHigh-throughput techniquesCohesin proteinsMyelodysplastic syndromeRNA splicingDNA methylationTranscription factorsDNA repairMolecular basisExpression profilingMalignant myeloid disordersBone marrow microenvironmentGenetic materialClonal architectureSuch mutationsTransduction elementsInflammatory bone marrow microenvironmentMarrow microenvironmentImportant substrateGenetic mutationsDiverse groupPathophysiology of MDS
2017
Bone marrow endothelial cells induce immature and mature B cell egress in response to erythropoietin
Ito T, Hamazaki Y, Takaori-Kondo A, Minato N. Bone marrow endothelial cells induce immature and mature B cell egress in response to erythropoietin. Cell Structure And Function 2017, 42: 17018. PMID: 29070774, DOI: 10.1247/csf.17018.Peer-Reviewed Original ResearchConceptsBone marrow endothelial cellsMarrow endothelial cellsStromal cellsEndothelial cellsEmergency hematopoiesisBone marrow stromal cellsMature B cellsPhosphorylation of STAT5Immature B cellsSpecific lineagesB cell egressCxcl12 transcriptionMarrow stromal cellsB cell retentionErythropoietin receptorBone marrow microenvironmentBone marrowHematopoietic stemB cellsPrecursor cellsPhenylhydrazine-induced hemolytic anemiaExpression levelsErythropoietin stimulationMesenchymal stromal cellsMarrow microenvironment
2015
Long-lived IgM plasma cells confer host protection against viral challenge (LYM6P.717)
Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, Mehr R, Mittler R, Kleinstein S, Sanz I, Jacob J. Long-lived IgM plasma cells confer host protection against viral challenge (LYM6P.717). The Journal Of Immunology 2015, 194: 135.5-135.5. DOI: 10.4049/jimmunol.194.supp.135.5.Peer-Reviewed Original Research
2011
A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma
Holkova B, Badros A, Geller R, Voorhees P, Zingone A, Korde N, Lin H, Tombes M, Shrader E, Sankala H, Kmieciak M, Roberts J, Sullivan D, Landgren O, Grant S. A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma. Blood 2011, 118: 2931. DOI: 10.1182/blood.v118.21.2931.2931.Peer-Reviewed Original ResearchPhase II studyAspartate aminotransferaseRefractory MMII studyCommon treatment-related adverse eventsPresent phase II studyTreatment-related adverse eventsTwo-stage Simon designAcute kidney injuryCommon grade 3Objective partial responsePeripheral sensory neuropathyECOG performance scoreRefractory multiple myelomaFavorable clinical profilePre-clinical activityResponse/resistanceEffects of AZD6244Multiple myeloma cellsCompetitive small molecule inhibitorBone marrow microenvironmentPost-treatment expressionOrtho BiotechPrior regimensStable disease
2009
Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species.
Chang M, Wey S, Lee A, Müschen M. Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species. Blood 2009, 114: 1976. DOI: 10.1182/blood.v114.22.1976.1976.Peer-Reviewed Original ResearchCML-like leukemiaBCR-ABL1Bone marrowLeukemia cellsReactive oxygen speciesImatinib sensitivityNOD/SCID recipientsG0/G1 cell cycle arrestNovel therapeutic approachesP210 BCR-ABL1G1 cell cycle arrestBone marrow cellsLevels of ROSBone marrow microenvironmentCell deathLeukemia cell survivalSCID recipientsCytokine primingFl miceCell cycle arrestOxygen speciesTherapeutic approachesCML cellsDay 4Leukemia growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply